Shanghai, China, 20 May 2021 - Shanghai MicroPort EP MedTech Co., Ltd. (“MicroPort® EP”) has recently obtained registration approval from the Ministry of Health of Kazakhstan (“MOH”) for multiple independently-developed products, marking its first entry into the Kazakhstani market.
In total, 17 devices and catheters were approved for use, including the Columbus® 3D EP Navigation System, the OptimAblate® Cardiac RF Generator, the OptimAblate® Irrigation Pump, the FireMagic® Cardiac RF Ablation Catheter Series, the EasyFinder® Diagnostic Catheter Series, the EasyLoop® Circular Mapping Catheter Series, the PathBuilder® Introducer Sets and the FORLNK™ Cable Series, which are primarily used for the diagnosis and effective treatment of cardiac arrhythmias.
Severe arrhythmia is the main cause of sudden cardiac death. While traditional pharmacological therapies can only control arrhythmias to a certain extent, the cardiac radiofrequency ablation procedure is a more effective non-pharmacological therapy in treating arrhythmias. The approved OptimAblate® Cardiac RF Generator can be used in RF ablation procedures to restore normal conduction of the heart by generating high-frequency energy to block or destroy abnormal pathways.
The OptimAblate® Irrigation Pump, which can be used in conjunction with OptimAblate® Cardiac RF Generator, is designed to achieve better ablation results by delivering constant flow of saline water to cool down the tip of the RF ablation catheter. By capturing and analyzing the electrophysiological activity of the heart, the Columbus® 3D EP Navigation System displays a real-time 3D image of the heart, offering physicians a better and more convenient surgical experience, while providing a safer, more effective and more affordable option for patients with arrhythmias.
Kazakhstan is the largest landlocked country in the world and a major hub in China’s “Belt and Road” initiative. MicroPort®’s Firehawk® Rapamycin Target Eluting Coronary Stent System and the Evermend® Occluder series, have already been used in clinical practice in the region. The approval of the above products by MicroPort® EP in Kazakhstan marks the availability of a broader line of MicroPort® heart disease treatment products in the local market, laying a solid foundation for its expansion in Central Asia.
In recent years, MicroPort® has been actively contributing to the “Belt and Road” Initiative by providing total medical solutions for doctors and patients in countries along the route. Responding to the situation that some “Belt and Road” countries are poorly equipped with medical equipment and have a limited number of surgeons who have received systematic training on minimally invasive surgery, MicroPort® has launched a number of projects over the years to provide education and exchange opportunities for local doctors, disseminating the latest information and sharing clinical experiences.
In the future, MicroPort® will continue to provide products and develop an academic exchange platform for medical professionals from the “Belt and Road” countries to support their training of professional techniques for the benefit of patients worldwide.
About MicroPort® EP
Shanghai MicroPort EP MedTech Co., Ltd, a subsidiary of MicroPort Scientific Corporation (MicroPort®, stock code: 00853.HK), was established in the Shanghai International Medical Zone on August 31, 2010. Its concentration is on the development, manufacture, and marketing of minimally invasive medical devices for the treatment of electrophysiological diseases, including cardiac ablation catheters, diagnostic catheters, 3D navigation systems, amongst others.